Objective: To describe the clinical, genetic, and epidemiologic features of hereditary spastic paraplegia (HSP) in Canada and to determine which clinical, radiologic, and genetic factors determine functional outcomes for patients with HSP.
sense and proprioception. Complex HSP forms are characterized by the presence of additional neurologic or nonneurologic features. 3 Genotype-phenotype relationships are not straightforward as HSP symptoms may occur at any age from infancy through late adulthood, and the age at symptom onset, rate of symptom progression, and extent of disability are variable even within HSP families with the same mutation. HSPs are genetically heterogeneous, and at least 77 different loci and 60 genes have been shown to be associated with HSP. The protein products have diverse roles, which include intracellular trafficking, endoplasmic reticulum-associated degradation, nucleotide metabolism, myelination, and mitochondrial metabolism. 4, 5 Many forms of HSP have been reported in Canada, but the prevalence, clinical types, genetic characterization, and functional impact of this condition remain poorly studied. We present a cross-sectional study of the clinical and genetic characteristics and functional outcomes of a large cohort of Canadian patients with HSP.
METHODS Clinical assessment. Five hundred twenty-six patients with a clinical diagnosis of HSP were recruited from 6 major medical centers across Canada (Toronto, Quebec, Montreal, Edmonton, Calgary, and Ottawa) from February 1, 2012 , to January 31, 2015. The diagnosis of HSP was based on previously published criteria. 6 Blood samples and clinical data were collected after written consent was obtained from all study participants. Standardized clinical assessments were performed and included demographic information, family history, developmental history, and HSP core symptoms (age at onset, lower extremity weakness and spasticity, hyperreflexia, extensor plantar responses, and bladder dysfunction). Other clinical symptoms such as progressive cognitive deficits, ataxia, extrapyramidal movements, swallowing difficulties, and ocular motor abnormalities were also assessed. For a subset of patients (n 5 65), disability was evaluated using the SPATAX-EUROSPA disability score, ranging from 0 (no disability) to 7 (severe disability/confined to bed). We also used the Spastic Paraplegia Rating Scale (SPRS), a previously validated disease-specific outcome measure for a subset of patients (n 5 48). The SPRS is a composite measure with the following subdomains: speed of gait, climbing stairs, quality of gait, arising from chair, quality of spasticity, weakness and contractures, and bladder dysfunction. All subdomains were rated on a scale between 0 and 4 with a maximum total score of 52. 7, 8 Ancillary investigations such as brain MRI, electrophysiologic tests, and metabolic studies were also evaluated. Patients with cerebellar signs were screened for mutations in FXN, SACS, and the common spinocerebellar ataxias (SCAs 1-8) prior to being included in the study. The complete data collection form is available as appendix e-1 at Neurology.org/ng. All data were stored in a central database at McGill University.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Research Ethics Boards of all institutions involved in the study (figure 1).
Genetic analysis/mutation screening. Genomic DNA was extracted from the peripheral blood according to standard procedures. 9 For a subset of the cohort from the province of Ontario (37 patients), all exons and flanking intron sequences of a panel of 51 genes known to cause HSP were sequenced both in forward and reverse directions at the Hospital for Sick Children using nextgeneration sequencing techniques. Sanger validation was performed according to standard protocols using BigDye terminator v1.1 (Life Technologies, Carlsbad, CA), and sequencing products were separated on an Applied Biosystems model 3730 Capillary Sequencer (Life Technologies) and analyzed using SeqPilot software (JSI Medical Systems, Kippenheim, Germany). Wholeexome sequencing was performed on 108 samples from 51 families without a genetic diagnosis, using the Agilent SureSelect Human All Exon v4 kit for capture and targeted enrichment of the exome. The captured samples were sequenced in the Illumina HiSeq 2000/ 2500 system (Genome Québec Innovation Centre, Montreal, QC, Canada). The reads were then aligned against the human genome (GRCh37 assembly) using Burrows-Wheeler Aligner. 10 Variant calling and annotation were performed using Genome Analysis ToolKit 11 and Annotate Variation. 12 The exome data were then screened for all known HSP-causing genes and mutations. 13, 14 Statistical analyses. For the purpose of statistical analysis, we analyzed only the 150 patients with a genetically confirmed diagnosis. Descriptive statistics were provided for demographic and clinical variables. Mean (SD), median, and interquartile range were calculated for continuous variables. Frequency count and percentages were provided for the categorical variables. We performed an ordered logistic regression to examine the association between ambulatory status and age at symptom onset. Linear regressions were used to analyze the association between disability and age at onset, and logistic regression was used to evaluate the association between disability and abnormal brain MRI. We investigated the association between genetic diagnoses and outcomes of interest including age at onset, disease duration, abnormal bladder function, swallowing difficulties, HSP-related symptoms, learning disabilities, speech delay, progressive cognitive deficits, motor delay, ambulatory status, age achieved walking, and disability scores. For each outcome of interest, we performed 5 univariate analyses with each gene as the covariate separately. Bonferroni correction technique was then used to adjust for multiple testing (adjusted p value threshold is 0.01). Logistic regressions were performed for binary outcomes. In cases of data point separation issues, Firth's penalized likelihood approach was applied. Linear regressions were conducted for continuous outcomes. We conducted a multiple linear regression analysis to examine the association between disability score (assessed by the SPRS) and variables such as genes of interest, age at evaluation, disease duration, abnormal brain MRI, and ataxia.
RESULTS Genetic testing. Of the 526 patients who met the inclusion criteria, 150 (28.5%) patients from 58 families were confirmed to have a genetic diagnosis. Mutations in a total of 15 different genes were identified in our cohort. The most frequent were SPAST (SPG4, 72 patients, 48%), ATL1 (SPG3A, 24 patients, 16%), SPG11 (12 patients, 8%), SPG7 (10 patients, 7%), and KIAA0196 (SPG8, 8 patients, 5%). Mutations were also found in PLP1 (SPG2, 5 patients, 3%), SLC2A1 (5 patients, 3%), CYP7B1 (SPG5A, 4 patients, 3%), VAMP1 (3 patients, 2%), ALS2 (2 patients, 1%), KIF5A (SPG10, 1 patient, 0.6%), SLC16A2 (SPG22, 1 patient, 0.6%), ZFYVE26 (SPG15, 1 patient, 0.6%), FA2H (SPG35, 1 patient, 0.6%), and PNPLA6 (SPG39, 1 patient, 0.6%) (figure 2 and table e-1). A total of 26 novel mutations were found in our cohort; they were absent in publically available databases (Single Nucleotide Polymorphism Database, 1000 Genomes Project, and Exome Aggregation Consortium) and were predicted to be pathogenic when evaluated using standard prediction programs (SIFT, PolyPhen, and Mutation Taster).
Clinical features. Seventy-eight of the 150 patients were men (52%). Ethnic group was self-reported, and 65% of the cohort was from North America, 29% from Europe, 2% from the Middle East, and 4% from Asia. Parental consanguinity was reported for 12/141 patients (8.5%). A positive family history (first-degree family members with symptoms of HSP) was reported by 87% of patients.
The mean age at evaluation of our cohort was 39.2 years (SD 22.1, range 1-82 years), and the mean age at onset of symptoms was 18.9 years (SD 18.6, range 0-67 years).
The majority of patients acquired independent walking by the age of 2 years (range less than 1 to 13 years). The most common clinical complaints, in addition to the core features of spasticity, weakness, and urinary disturbance, were dysarthria (33%), sensory abnormalities (35%), motor delay (24%), peripheral neuropathy (23%), speech delay (18%), and ataxia (17%). Less common symptoms included ocular motor disturbance (11%), intentional tremor (11%), and seizures (3%).
Brain MRI was available for 60 patients. Brain imaging was abnormal in 28% of the cohort (17/ 60). The most common abnormalities reported were thin corpus callosum (6 patients, 10%), followed by cerebellar atrophy (5 patients, 8%), and white matter abnormalities (4 patients, 7%). Two patients had nonspecific abnormalities on brain imaging.
Functional outcomes. At the time of evaluation for this study, 36/56 patients (64%) required an aid for ambulation with the mean age at onset of mobility aid use of 33.6 years (SD 23.3, range 2-68 years). Twelve patients required the use of a cane (21%) and 3 used a walker (5%). Approximately one-third of our cohort was independent with respect to ambulation (20/56 patients, 36%); however, 21 patients (38%) were using a wheelchair. The mean SPRS for the subset of our cohort for which this was available (48 patients) was 19 (SD 11, range 2-39), and the majority of patients (48/65, 74%) had SPATAX-EUROSPA disability scores within the mild to moderate range.
On univariate analysis, there was no statistically significant association between age at symptom onset and ambulatory status, nor was there a statistically significant association between age at symptom onset and SPRS score when adjusted for age at evaluation. There was a clear association between abnormal brain MRI and disability as measured by the SPRS, as patients with abnormal brain MRI had a mean higher SPRS score of 10.49 compared to those with normal brain imaging (p 5 0.0037).
Genotype-phenotype correlations. Linear regression analysis with Bonferroni correction revealed that patients with SPG4 and SPG7 were more likely to develop symptoms later compared to other HSP subtypes, with a mean age at symptom onset of 24.6 (standard error [SE] 3.2) years for SPG4 (p 5 0.0017) and 33 (SE 6.0) years for SPG7 (p 5 0.013). Patients with SPG3A were more likely to present at a younger age, with a mean age at symptom onset of 10.1 (SE 4.4) years (p 5 0.022) (figure 3). SPG4 appeared to be associated with greater risk of bladder dysfunction (odds ratio (OR) 2.24, 95% confidence interval (CI)
Similarly, SPG11 appeared to be associated with increased pain due to HSP-related symptoms compared to other genetic diagnoses (OR 5.44, 95% CI 1.08-27.37, p 5 0.039), but this was not statistically significant following Bonferroni correction. SPG2 appeared to be associated with an increased risk of speech delay (OR 18.33, 95% CI 1.71-196.19, p 5 0.016) and motor delay (OR 11.8, 95% CI 1.14-122.1, p 5 0.04), and SPG4 less likely to have motor delay (OR 0.10, 95% CI 0.01-0.78, p 5 0.028), but these observations were no longer statistically significant after Bonferroni correction. SPG11 Figure 3 Correlation between genotype and age at onset
Patients with SPG4 and SPG7 were more likely to develop symptoms later compared to other hereditary spastic paraplegia subtypes, while patients with SPG3A were more likely to present at a younger age. The rectangles span the first quartile to the third quartile (interquartile range). The horizontal line inside the rectangle shows the median, and the "whiskers" above and below the box represent the minimum and maximum values of the ages at symptom onset.
was We conducted a cross-sectional study of a large, ethnically diverse cohort of patients with HSP in Canada using standardized clinical assessments and specifically assessed functional outcomes using validated rating scales. As in previously published population-based studies, SPG4 and SPG3A were the most frequent AD-HSP. 15, 20, 21 SPG4 accounts for up to 45% of AD-HSP and up to 20% of sporadic cases, 22 while SPG3A accounts for nearly 10% of AD-HSP.
18 SPG8 was present in 5% of our cohort, which is more common compared to previous reports. 23 SPG11 followed by SPG7 were the most frequent AR-HSP, which is also in keeping with previously published studies. 24, 25 The primary analysis of the exome data was focused on known HSP genes; however, mutations were also found in genes not typically considered HSP genes in patients who met the clinical criteria for HSP (1 patient with a mutation in SLC16A2, 3 patients with mutations in VAMP1, and 4 patients from a single family with mutations in SLC2A1). This has been observed by other groups and further highlights the clinical and genetic heterogeneity of HSP. 19 In contrast to comparable neurodegenerative disorders such as the SCAs, very little is known about functional outcomes in patients with HSP, and the majority of studies are focused exclusively on SPG4 and SPG3A. 20, 26, 27 This is likely due to very recent advances in genetic diagnoses of HSP compared to the common SCAs and highlights the need for good natural history data to identify parameters which influence clinical outcomes of HSP. 28 There is one study which examined the correlation between disease duration and spasticity in patients with HSP, but unfortunately, the genetic diagnoses were not reported. 29 Another study identified the degree of spasticity as being the most important contributing factor for wheelchair dependence. 30 Higher SPRS scores have been shown to be inversely correlated with quality of life in a previous study. 31 As the majority of patients in our cohort who met the clinical criteria for HSP did not have a genetic diagnosis, this illustrates the need for studies of clinical parameters which influence prognosis and outcomes for these patients. To our knowledge, only 1 recent study has focused on functional outcomes in a large genetically confirmed HSP population, the majority of which were adults with SPG4 of German ancestry. 19 In contrast to the findings from this study, we did not observe a statistically significant association between disability scores and age at symptom onset or disease duration. This may reflect the underlying differences between our patient populations (ethnically diverse population from Canada vs primarily German ethnicity) and the large proportion of pediatric patients in our study. In our cohort, patients with SPG4 and SPG3A had less severe disability scores compared with other HSP genetic subtypes, and patients with SPG11 and SPG2 had more severe scores, although the samples sizes were too small for this observation to reach statistical significance. Bladder dysfunction is a recurrent and disabling symptom, 32 which was present in a large proportion of our cohort, with the exception of patients with SPG3A, which may contribute to the better functional outcomes observed in this subgroup of patients.
The clear correlation between abnormal brain MRI and increased disability scores in our cohort confirms that brain imaging is an essential tool for clinical diagnosis and also for prognostication. 33, 34 The diagnostic utility of brain imaging to identify specific features of genetic subtypes of HSP such as SPG2, SPG7, SPG11, or SPG35 is well established. 34, 35 As an example, patients with SPG11 have thinning or agenesis (partial or complete) of the corpus callosum. 36 They also demonstrate prominent cognitive impairment and learning disabilities, 37, 38 and some patients with SPG11 mutations present with a very rare phenotype (Kjellin syndrome) where mental retardation is a predominant feature. 39 The clinical spectrum associated with SPG7 mutations is variable, but specific brain MRI findings such as cerebellar atrophy is common, which is consistent with ataxia being the first clinical symptom in many of these patients. 40 Prospective studies of brain imaging in patients with HSP will be necessary to define the CNS phenotypes of the genetic HSP subtypes. The use of advanced techniques such as fractional anisotropy reduction, spinal morphometry, or diffusor tensor imaging brain will allow identification of imaging biomarkers which could be used to monitor the progression of the disease, and eventually used as outcome measures for future clinical trials.
One major strength of our study was the inclusion of both adult and pediatric patients, which enabled accurate assessment of age at symptom onset, and other clinical parameters essential for delineating the natural history of these disorders. Our study was limited by the relatively small sample sizes of the genetic subtypes of HSP, with the exception of SPG3A, SPG4, SPG11, and SPG7. The clinical variability between patients with the same genetic subtype, and even within the same family, renders accurate genotype-phenotype correlations difficult. Large prospective studies of well-phenotyped patients are required to define the natural history of the various HSP subtypes and to design appropriate clinical trials of therapies for these complex disorders.
CONCLUSION HSP is usually not a life-limiting disorder but can be associated with serious disability, and accurate genetic diagnosis, genetic counseling, and management of symptoms are essential to optimizing care for patients with HSP and their families. The Canadian HSP population is characterized by considerable clinical and genetic heterogeneity, yet we observed meaningful genotypephenotype correlations such as SPG4 and SPG7 presenting at later onset compared to SPG3A. SPG11 is strongly associated with abnormal brain MRI but also with prominent learning disabilities, progressive cognitive deficits, and poor functional outcomes. Patients with SPG3A and SPG4 have less disability and are less likely to develop cognitive deficits. Brain MRI is the most useful tool to predict functional outcomes and disabilities and should always be integrated in the clinical evaluation of any patient with suspected HSP.
Accurate molecular characterization of wellphenotyped cohorts and international collaboration to increase the power of future studies will be critical to establish the natural history of these rare degenerative disorders to enable future clinical trials.
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